RE:RE:Good conference callI cannot figure how they have 40% market share in the US, Agg earned $5million US dollars ($7million CND)...the total US market for this class is is around $50-60million?? I thought it was much higher.
As for the "high-value" generic, high value and generic are usually not associated with one another. Generic status is a free-for all for anyone that wants to jump on board. Who are the competitors? Teva, Mylan? If so, were screwed. And the agreement set up income wise is another screw job. 50-50 revenue split with the manufacturer (Apicore) when sales costs (Medicure) is much higher. I am beginning to understand now why Dawson left.